Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,361 active trials259 approved drugs3,860 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03024489 | Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 27 | Mahidol UniversityOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT04903873 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 110 | EutilexINDUSTRY | 2 | Mar 15, 2024 | clinicaltrials |
| Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis |
| unknown |
| Phase 2 |
| 9 |
| Massachusetts General HospitalOTHER |
| 1 |
| Mar 13, 2024 |
| clinicaltrials |
| NCT04249739 | Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive | unknown | Phase 2 | 93 | Samsung Medical CenterOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT06308939 | Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial | unknown | Phase 2 | 81 | Zhejiang Cancer HospitalOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT03951337 | 64Cu-ATSM PET/CT in Rectum Cancer (TEP 64Cu-ATSM-Rectum) | unknown | Phase 2 | 70 | Institut Cancerologie de l'OuestOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT03975907 | Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1) | unknown | Phase 1 / Phase 2 | 121 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT04062656 | Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG(IMAGINE) | unknown | Phase 2 | 21 | University Hospital, EssenOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05004974 | Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 20 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05387616 | A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden(Alternative-C) | unknown | Phase 2 | 98 | Ludwig-Maximilians - University of MunichOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06277674 | Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI | unknown | Phase 2 | 20 | Guangzhou University of Traditional Chinese MedicineOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT05111860 | Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy | unknown | Phase 1 / Phase 2 | 20 | Shanghai Minimally Invasive Surgery CenterOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06259721 | Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 22 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT03549715 | NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma(NEMIO) | unknown | Phase 1 / Phase 2 | 121 | Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05011227 | Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma | unknown | Phase 2 | 100 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05066607 | Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy(IsAMYP) | unknown | Phase 2 | 46 | Intergroupe Francophone du MyelomeNETWORK | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05370547 | Chidamide Bridging for CAR-T Therapy | unknown | Phase 1 / Phase 2 | 120 | Chinese PLA General HospitalOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05910177 | Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin | unknown | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06237413 | A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours | unknown | Phase 1 / Phase 2 | 110 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06242249 | Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 10 | Shahid Beheshti University of Medical SciencesOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04597476 | A Randomized, Double-blind Study to Evaluate the Clinical Effect and Safety of Fucoidan in Patients With Squamous Cell Carcinomas of the Head and Neck | unknown | Phase 2 | 119 | Hi-Q Marine Biotech International, Ltd.INDUSTRY | 1 | Mar 5, 2024 | clinicaltrials |
| NCT04879654 | Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic Surgery(SNMM) | unknown | Phase 2 | 45 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT04780217 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 42 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06290817 | Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI | unknown | Phase 2 | 62 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT04739670 | Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer(BELLA) | unknown | Phase 2 | 31 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT03428373 | Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma(RithMM) | unknown | Phase 2 / Phase 3 | 57 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT03666559 | Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation(AGIR) | unknown | Phase 2 | 8 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT06280690 | SGM-101 Tumor Targeted Fluorescence Endoscopy in Rectal Polyps With Suspected T1 Adenocarcinoma or High Grade Dysplasia(SGM-T1) | unknown | Phase 2 | 20 | Leiden University Medical CenterOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT06284746 | Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer | unknown | Phase 2 | 80 | Lin ChenOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT06285019 | Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 65 | Fudan UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT06285136 | Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult | unknown | Phase 2 / Phase 3 | 40 | The Second Affiliated Hospital of Kunming Medical UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT03865511 | MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib(MELROSE) | unknown | Phase 2 | 150 | Nantes University HospitalOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04641078 | Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer(DART) | unknown | Phase 2 | 124 | University Hospital, GhentOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05033925 | Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients | unknown | Phase 1 / Phase 2 | 324 | Gadjah Mada UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05627752 | Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage | unknown | Phase 2 / Phase 3 | 120 | Zhongnan HospitalOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06279767 | Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma | unknown | Phase 1 / Phase 2 | 27 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT03576378 | BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL) | unknown | Phase 1 / Phase 2 | 41 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT04378647 | BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant(BRESELIBET) | unknown | Phase 2 | 150 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT04492293 | An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer | unknown | Phase 2 | 115 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05122091 | Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma | unknown | Phase 2 | 53 | Guangxi Medical UniversityOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05163080 | SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)(SURVIVE) | unknown | Phase 2 | 247 | MimiVax, LLCINDUSTRY | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05371223 | Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic Nabpaclitaxel-Gemcitabine Chemotherapy for Pancreatic Cancer Peritoneal Metastases(Nab-PIPAC) | unknown | Phase 2 | 38 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05574881 | Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer | unknown | Phase 1 / Phase 2 | 72 | Fudan UniversityOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05178043 | GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 5 | Suzhou Kintor Pharmaceutical Inc,INDUSTRY | 1 | Feb 22, 2024 | clinicaltrials |
| NCT02077335 | Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer | unknown | Phase 2 | 50 | CSSS de GatineauOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT04096417 | Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations | unknown | Phase 2 | 14 | Academic and Community Cancer Research UnitedOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05924997 | Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 52 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT01754402 | Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma | unknown | Phase 1 / Phase 2 | 56 | Cristina GasparettoOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03375983 | Plasmodium Immunotherapy for Advanced Cancers | unknown | Phase 1 / Phase 2 | 20 | CAS Lamvac Biotech Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03474822 | Plasmodium Immunotherapy for Breast and Liver Cancers | unknown | Phase 1 / Phase 2 | 60 | CAS Lamvac Biotech Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Mar 15, 2024source: clinicaltrials